Could 8 weeks of TB drugs be enough? new trial aims to find out
NCT ID NCT07163143
First seen Sep 30, 2025
Summary
This study looks at people who have chest X-ray signs of TB but whose sputum tests are negative. It tests whether shorter treatment (8 to 24 weeks) works as well as the standard 24-week course. 784 participants will be randomly assigned to different treatment lengths or close monitoring without immediate treatment. The goal is to find the shortest effective treatment and understand who can safely avoid treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS (TB) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bulawayo City Health
Bulawayo, Zimbabwe
Contact Email: •••••@•••••
-
Clinical HIV Research Unit, Wits Health Consortium
Johannesburg, South Africa
Contact Email: •••••@•••••
-
National University of Medical Sciences
Islamabad, Pakistan
Contact Email: •••••@•••••
-
The Aurum Institute
Johannesburg, South Africa
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isoniazid, rifampicin, pyrazinamide, ethambutol (standard TB drugs)
What this could lead to
If successful, this could show that shorter TB treatment (8 weeks) is as effective as the standard 24 weeks, reducing side effects and burden for patients.
What could go wrong
This is a Phase 3 trial, but it focuses on a specific group (people with negative sputum tests). Results may not apply to all TB cases, and shorter treatment might still lead to relapse.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.